Amrita Desai - Concepedia

Concepedia

Author

Amrita Desai

University of California, Los Angeles

Also Known As

A Desai, A. Desai, Amrita Desai, Amrita J Desai, Amrita J. Desai, Shaykevich, Tamara

129

Publications

3.1K

Citations

21

H-Index

28

Concepts

All Affiliations

University of California, Los Angeles University of Miami Sylvester Comprehensive Cancer Center Pfizer (United States)University of North Carolina at Chapel Hill

AD

About

Amrita Desai is an author at University of California, Los Angeles specializing in oncology, medicine, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	523
2	Cell Biology	5	5	287
3	Pathology	4	4	174
4	Health Sciences	2	2	99
5	Immunology	2	2	97

Amrita Desai

×

22

Publications

3.1K

Citations

21

H-Index

	Year	Citations
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro Richard S. Finn, Judy Dering, Dylan Conklin, Breast Cancer Research	2009	1.4K
Genetic Map of Diploid Wheat, <i>Triticum monococcum</i> L., and Its Comparison With Maps of <i>Hordeum vulgare</i> L. Jorge Dubcovsky, Ming‐Cheng Luo, Gan‐Yuan Zhong, Genetics	1996	271
Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006 Karen H. Costenbader, Amrita Desai, Graciela S. Alarcón, Arthritis & Rheumatism	2011	230
Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab <i>In vitro</i> and <i>In vivo</i> Zev A. Wainberg, Adrian Anghel, Amrita Desai, Clinical Cancer Research	2010	209
PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity. Joshua E. Logan, Nikayeh Mostofizadeh, Amrita Desai, PubMed	2013	102
Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib Ondrej Kalous, Dylan Conklin, Amrita Desai, Molecular Cancer Therapeutics Human EgfBreast OncologyOncologyIrreversible Pan-her InhibitorMedicine	2012	84
Long-term course of patients with primary ocular adnexal MALT lymphoma: a large single-institution cohort study Amrita Desai, Madhura Joag, Lazaros J. Lekakis, Blood	2016	78
Risk Factors for Transformation to Higher-Grade Lymphoma and Its Impact on Survival in a Large Cohort of Patients With Marginal Zone Lymphoma From a Single Institution Juan Pablo Alderuccio, Wei Zhao, Amrita Desai, Journal of Clinical Oncology	2018	75
Inhibition of HSP90 with AUY922 Induces Synergy in HER2-Amplified Trastuzumab-Resistant Breast and Gastric Cancer Zev A. Wainberg, Adrian Anghel, Amy M. Rogers, Molecular Cancer Therapeutics	2013	68
Identification of Common Predictive Markers of <i>In vitro</i> Response to the Mek Inhibitor Selumetinib (AZD6244; ARRY-142886) in Human Breast Cancer and Non–Small Cell Lung Cancer Cell Lines Edward B. Garon, Richard S. Finn, Wylie Hosmer, Molecular Cancer Therapeutics PathologyHuman Breast CancerCancer BiologyTumor BiologyCommon Predictive Markers	2010	66

Page 1